Employees: 1,106
Size JW Pharmaceutical (001060.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $423M, the 387th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩23,200 on 18 Nov 2026.
Performance Over six months the shares fell 25.9%, against -21.1% for the median peer and -37.2% for the South Korea market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 9.0% over the last twelve months (peer median +3.4%); the operating margin is 13.4% (peer median -10.6%).
Valuation It trades at 6.3× forward earnings against a peer median of 17.8× (cheapest of 7).
Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -23 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 11.7 points above its cost of capital (6.9% WACC).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩833B | ₩775B | ₩719B | ₩749B | ₩684B |
| Revenue growth | — | +8% | -4% | +9% | — |
| Gross profit | ₩397B | ₩359B | ₩323B | ₩336B | ₩288B |
| EBITDA | ₩131B | ₩107B | ₩102B | ₩119B | ₩77.3B |
| Net income | ₩87.0B | ₩58.3B | ₩61.7B | ₩35.1B | ₩30.3B |
| Free cash flow | ₩106B | ₩84.6B | ₩71.1B | ₩59.9B | ₩46.8B |
| Capital expenditure | ₩29.6B | ₩36.1B | ₩28.1B | ₩43.0B | ₩12.4B |
| Total debt | ₩69.1B | ₩54.6B | ₩91.7B | ₩170B | ₩210B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 001060.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.4% | -13.0% | 6th highest of 21 |
| 6-month return | -25.9% | -21.1% | 11th highest of 21 |
| Distance from 52-week high | -40.9% | -51.3% | 7th highest of 21 |
| Revenue growth (TTM) | +9.0% | +3.4% | 9th highest of 19 |
| Operating margin | 13.4% | -10.6% | 2nd highest of 19 |
| Forward P/E | 6.3× | 17.8× | cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | -15.4% | 3.4% | least demanding of 7 |
| Growth delivered (Del g) | +7.2% | +4.7% | 4th highest of 7 |
| Hurdle (Req g minus delivered) | -22.6 pp | +1.3 pp | least demanding of 7 |
| ROIC minus cost of capital | +11.7 pp | -8.2 pp | 2nd highest of 18 |
| EV / EBITDA | 4.4× | n/a | — |
| Net debt / EBITDA | 0.1× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| JW Pharmaceutical 001060.KS | South Korea | $423M | -26% | +9% | 13% | 6.3× | -15.4% | +7.2% |
| Beijing Foyou Pharma 601089.SS | China | $423M | -27% | +5% | 10% | 11.8× | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $423M | -1% | +21% | 10% | n/a | 5.4% | +15.3% |
| Tevogen TVGN | United States | $422M | -38% | n/a | n/a | n/a | n/a | n/a |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $421M | -31% | +1% | -39% | n/a | n/a | n/a |
| Hyundai Bioscience 048410.KS | South Korea | $424M | -50% | +78% | -580% | n/a | n/a | n/a |
| Teyi Pharmaceutical 002728.SZ | China | $419M | -12% | -7% | 7% | 28.0× | 24.4% | +8.0% |
| Ovid Therapeutics OVID | United States | $427M | -5% | -78% | -4,700% | n/a | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $427M | +9% | +69% | -16% | n/a | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $427M | +4% | -4% | 3% | n/a | 10.6% | +1.4% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $430M | -30% | +14% | 5% | n/a | 1.4% | -1.3% |
| Phathom Pharmaceuticals PHAT | United States | $431M | -55% | +87% | -9% | 39.5× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $433M | -48% | +51% | 27% | 12.5× | -0.2% | +14.5% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $433M | -47% | +35% | 4% | 10.3× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $433M | -42% | -14% | -12% | 23.1× | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $412M | +64% | +6,162% | -194% | n/a | n/a | n/a |
| Rezolute RZLT | United States | $411M | +32% | n/a | n/a | n/a | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $410M | -49% | -88% | -676% | n/a | n/a | n/a |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $437M | -8% | -17% | -28% | n/a | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $437M | -12% | -49% | 5% | n/a | -5.6% | -5.6% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $437M | -16% | -5% | -29% | n/a | n/a | n/a |